1. Is telomerase a viable target in cancer?
   C.M. Buseman et al, 2012, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis CrossRef
2. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines
   Atsuko Sakakibara et al, 2011, Auris Nasus Larynx CrossRef
3. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma
   Ana Markovic et al, 2012, Expert Review of Anticancer Therapy CrossRef
4. Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer
   Gamze Ugurluer et al, 2014, Expert Opinion on Investigational Drugs CrossRef
5. FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer
   C T Karadedou et al, 2012, Oncogene CrossRef
6. Optical Molecular Imaging of Multiple Biomarkers of Epithelial Neoplasia: Epidermal Growth Factor Receptor Expression and Metabolic Activity in Oral Mucosa
   Kelsey J. Rosbach et al, 2012, Translational Oncology CrossRef
7. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma
   X. F. Guo et al, 2013, Diseases of the Esophagus CrossRef
8. Pharmacotherapy for squamous-cell carcinoma of the head and neck
   Giorgos Papaspyrou et al, 2011, Expert Opinion on Pharmacotherapy CrossRef
9. Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA)
   Guo-Feng Shen et al, 2015, Journal of Photochemistry and Photobiology B: Biology CrossRef
10. An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma
    Shunsuke Gohara et al, 2022, Molecular Therapy - Oncolytics CrossRef
11. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Mark Agulnik, 2012, Medical Oncology CrossRef
12. Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer
    Xiao-fang Guo et al, 2018, Cancer Chemotherapy and Pharmacology CrossRef
13. Progress in the Application of Targeted Agents in Non-small Cell Cancer
    Zhihao Long, 2023, International Journal of Biology and Life Sciences CrossRef
14. Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer
    Zhan Wang et al, 2023, Cancers CrossRef
15. Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin‐2 gene
    Bin Xu et al, 2012, Cancer CrossRef
16. Ah receptor antagonism inhibits constitutive and cytokine inducible IL6 production in head and neck tumor cell lines
    Brett C. DiNatale et al, 2011, Molecular Carcinogenesis CrossRef
17. Association of oncolytic adenoviruses with chemotherapies: An overview and future directions
    Christian Bressy et al, 2014, Biochemical Pharmacology CrossRef
18. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer
    Ranee Mehra et al, 2011, Drug Resistance Updates CrossRef
19. Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas
    Shuhei Osaki et al, 2016, Scientific Reports CrossRef
20. Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer
    Wataru Ishikawa et al, 2020, Molecular Therapy - Oncolytics CrossRef
21. A review on the advances and challenges of immunotherapy for head and neck cancer
    Gang Cheng et al, 2021, Cancer Cell International CrossRef
22. From infection to immortality: The role of HPV and telomerase in head and neck cancer
    Silvia Giunco et al, 2025, Oral Oncology CrossRef
23. Telomerase‐specific oncolytic adenovirus: Antitumor effects on radiation‐resistant head and neck squamous cell carcinoma cells
    Hideaki Takahashi et al, 2014, Head & Neck CrossRef
24. Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts
    Jolijn W. Groeneweg et al, 2014, Clinical Cancer Research CrossRef
25. HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations
    Edward L Nelson, 2014, Clinical Investigation CrossRef
26. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies
    Jonathan Moreira et al, 2017, Drugs CrossRef
27. One Potential Oncolytic Adenovirus Expressing Lipocalin-2 for Colorectal Cancer Therapy
    Bin Xu et al, 2013, Cancer Biotherapy and Radiopharmaceuticals CrossRef
28. HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma
    Netanya I. Pollock et al, 2015, Clinical Cancer Research CrossRef
29. Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer
    Tsung-Jang Yeh et al, 2023, Biomedicines CrossRef
30. Self-Assembly of pH-Labile Polymer Nanoparticles for Paclitaxel Prodrug Delivery: Formulation, Characterization, and Evaluation
    Shani L. Levit et al, 2020, International Journal of Molecular Sciences CrossRef
31. Fighting Fire with Fire: Rewiring Tumor Cells for Oncolytic Virotherapy
    Douglas J Mahoney et al, 2012, Future Oncology CrossRef
32. Rapid Self-Assembly of Polymer Nanoparticles for Synergistic Codelivery of Paclitaxel and Lapatinib via Flash NanoPrecipitation
    Shani L. Levit et al, 2020, Nanomaterials CrossRef
33. Macrophages M2 polarization is involved in lapatinib-mediated chemopreventive effects in the lung cancer
    Muhammad Tariq et al, 2023, Biomedicine & Pharmacotherapy CrossRef